Computed tomography‐defined low skeletal muscle index and density in cancer patients: observations from a systematic review

• Published in: Journal of cachexia, sarcopenia and muscle Vol. 12; no. 6; pp. 1408 - 1417
• Main Authors: McGovern, Josh, Dolan, Ross D., Horgan, Paul G., Laird, Barry J., McMillan, Donald C.
• Format: Journal Article
• Language: English
• Published: Germany John Wiley & Sons, Inc 01.12.2021; John Wiley and Sons Inc; Wiley
• Subjects: Anthropomorphism; Body Composition; Cancer; Colorectal cancer; Esophageal cancer; Gastric cancer; Humans; Lung cancer; Lung Neoplasms; Muscle, Skeletal - diagnostic imaging; Musculoskeletal system; Pancreatic cancer; Prado, Martin; Prognosis; Review; Reviews; Sarcopenia; Systematic review; Tomography; Tomography, X-Ray Computed; Tumors; Vertebrae; CT; Body composition; Cancer
• ISSN: 2190-5991; 2190-6009
• DOI: 10.1002/jcsm.12831

Background Computed tomography (CT) analysis of body composition has garnered interest as a potential prognostic tool in those with cancer. A range of pre‐defined thresholds currently exist within the literature to define low skeletal muscle mass and density. The aim of the present systematic review was to assess the prevalence of low skeletal muscle index (SMI) and density (SMD) within the literature, across a range of common solid tumours. Methods A systematic search of PubMed was carried out to identify studies reporting CT analysis of SMI and SMD in patients with colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast, and lung cancer. The type of cancer, whether curative or non‐curative disease, the anthropomorphic parameter studied, threshold used to define low SMI and SMD, and the prevalence of these anthropomorphic measurements within the population were recorded. Results Of the 160 studies included, 156 reported an assessment of SMI and 35 reported assessment of SMD. The median prevalence of low SMI was 43% (30.1–57.1) and low SMD 49.4% (31.7–58.5) across the entire cohort. There was little variation in the prevalence of low SMI and SMD when studies were divided into curative and non‐curative cohorts—40.7% (27.5–51.3) vs. 48.4% (30.9–60.1) and 37.8% (32.2–52.2) vs. 55.3% (38.5–64.7) respectively. When divided into colorectal, oesophageal, gastric, hepatobiliary, pancreatic, breast and lung cancers, similar prevalence of low SMI (46.0% %, 49.8%, 35.7%, 41.1%, 32.3%, 34%, and 49.5%) and low SMD were also observed (52.1%, 54.3%, 71.2%, 56.8%, 55.3%, and 52.6%). This was maintained when studies were stratified into cohorts by threshold used—low SMI (Martin 48.9%, Prado 49.9%, and Others 36.0%) and low SMD (Martin 52.4% and Others 48.6%). Conclusions Low SMI and SMD are endemic across a range of cancer types and disease stage, challenging pre‐existing dogma of the determinants of prevalence.